Desmoid Tumors Market, By Drug Type, By Distribution channel, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
Description
REPORT HIGHLIGHT
Desmoid Tumors Market size was valued at US$ 2,965.91 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.
Desmoid tumors are rare non-cancerous (benign) tumors that form from connective tissue cells, typically in the fascia, which surrounds muscles, nerves, and blood vessels. These tumors are locally aggressive, which means that they can grow and invade nearby structures but do not spread to other parts of the body like traditional cancer.
Desmoid Tumors Market- Market Dynamics
Rising Global Cancer Incidence Fuels Growth In The Desmoid Tumor Market
Rising cancer rates are expected to drive future growth in the desmoid tumor market. Cancer is a group of disorders characterized by the body's abnormal cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs, causing damage. The rising number of cancer cases worldwide has increased the demand for effective and advanced chemotherapeutic agents, which has a positive impact on the desmoid tumor market. For instance, in May 2024, according to the National Cancer Institute, a federal government agency based in the United States In 2024, an estimated 2,001,140 new cancer cases will be diagnosed in the United States, with 611,720 deaths expected due to the disease. In 2022, there were nearly 20 million new cancer cases and 9.7 million deaths worldwide. By 2040, the annual number of new cancer cases is expected to reach 29.9 million, with 15.3 million cancer-related deaths. As a result, rising cancer rates are driving the growth of the desmoid tumor market.
Desmoid Tumors Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.20% over the forecast period (2025-2032)
Based on Drug Type segmentation, the chemotherapy segment is the largest in the global market in 2025
Based on Distribution channel segmentation, the hospital pharmacies segment is anticipated to hold the majority of the global market.
On the basis of region, North America was the leading revenue generator in 2024
Desmoid Tumors Market- Segmentation Analysis:
The Global Desmoid Tumors Market is segmented on the basis of Drug Type, Distribution channel, and Region.
The market is divided into five categories based on Drug Type: Non-steroidal anti-inflammatory drugs (NSAIDs), Chemotherapy, Targeted Therapy, Hormone Therapy and Others. The chemotherapy segment is the largest in the global market in 2025, and it is expected to continue to dominate the market during the forecast period. Chemotherapy, while traditionally associated with systemic side effects, remains an important treatment option, particularly for aggressive or inoperable tumors. Combination drug regimens tailored to individual patient needs have increased efficacy and tolerability. Furthermore, ongoing research into new chemotherapeutic agents with better safety profiles is expected to fuel growth in this segment. Despite its challenges, chemotherapy is still an important part of the treatment arsenal.
The market is divided into three categories based on Distribution channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is expected to account for the majority of the global market during the forecast period. Hospital pharmacies are an important distribution channel for desmoid tumor treatments because they have direct access to patients receiving treatment in healthcare facilities. These pharmacies ensure the availability of essential medications and serve as a vital link between healthcare providers and patients. Their role in managing medication supply and offering counseling services is critical to the overall treatment process.
Desmoid Tumors Market- Geographical Insights
North America is the largest regional segment in the global desmoid tumors market, and it is expected to maintain its lead position during the forecast period. Rising healthcare expenditure, rapid adoption of technological advancements, growing awareness, and rising prevalence of desmoid tumors in North America all contribute to the market's growth. Imaging advancements, such as MRI and CT scans, have improved the ability to detect and locate desmoid tumors.
The Asia-Pacific region is expected to have the highest CAGR in the global market over the forecast period. The growing patient population, increased healthcare investments and infrastructure development, and increased awareness of rare diseases and access to healthcare are the primary drivers of the desmoid tumors market in Asia-Pacific.
Desmoid Tumors Market- Competitive Landscape:
The desmoid tumors market is competitive, with pharmaceutical companies and research institutions all working to develop effective treatment options. Key players include Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, and Amneal Pharmaceuticals LLC, which has participated in clinical trials for targeted therapies. Smaller biotech firms and academic institutions focused on innovative research and development contribute to the market as well. Competition is driven by the need to improve treatment outcomes, reduce side effects, and meet patients' unmet medical needs. This includes both the development of new therapies, such as targeted drugs and immunotherapies, and the enhancement of existing treatments. Regulatory approvals, clinical trial results, and patentability all have an impact on the competitive environment.
Recent Developments:
In August, 2023, Horizon Therapeutics Plc has announced the launch of Krystexxa® (PEGylated brentuximab vedotin) for injection in the United States for the treatment of adult patients with unresectable or recurrent locally advanced or metastatic soft tissue sarcoma (STS) who have previously received anthracycline-containing chemotherapy.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DESMOID TUMORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Horizon Therapeutics Plc
Strides Pharma Science Limited
Teva Pharmaceutical Industries Ltd
Amneal Pharmaceuticals LLC
Hikma Pharmaceuticals PLC
Natco Pharma Ltd
Lupin, Zydus Lifesciences
Mylan N.V.
Assertio Holdings, Inc.
Mayne Pharma Group Limited
Alembic Pharmaceuticals Limited, Aprazer
Ayala Pharmaceuticals
SpringWorks Therapeutics, Inc
Iterion Therapeutics
Novartis AG
Apotex Inc.
Bayer AG
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd
Endo International plc
Abbott
Getwell Pharmaceuticals
Others
GLOBAL DESMOID TUMORS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
Non-steroidal anti-inflammatory drugs(NSAIDs)
Chemotherapy
Targeted Therapy
Hormone Therapy
Others
GLOBAL DESMOID TUMORS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
GLOBAL DESMOID TUMORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA
Desmoid Tumors Market size was valued at US$ 2,965.91 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.
Desmoid tumors are rare non-cancerous (benign) tumors that form from connective tissue cells, typically in the fascia, which surrounds muscles, nerves, and blood vessels. These tumors are locally aggressive, which means that they can grow and invade nearby structures but do not spread to other parts of the body like traditional cancer.
Desmoid Tumors Market- Market Dynamics
Rising Global Cancer Incidence Fuels Growth In The Desmoid Tumor Market
Rising cancer rates are expected to drive future growth in the desmoid tumor market. Cancer is a group of disorders characterized by the body's abnormal cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs, causing damage. The rising number of cancer cases worldwide has increased the demand for effective and advanced chemotherapeutic agents, which has a positive impact on the desmoid tumor market. For instance, in May 2024, according to the National Cancer Institute, a federal government agency based in the United States In 2024, an estimated 2,001,140 new cancer cases will be diagnosed in the United States, with 611,720 deaths expected due to the disease. In 2022, there were nearly 20 million new cancer cases and 9.7 million deaths worldwide. By 2040, the annual number of new cancer cases is expected to reach 29.9 million, with 15.3 million cancer-related deaths. As a result, rising cancer rates are driving the growth of the desmoid tumor market.
Desmoid Tumors Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.20% over the forecast period (2025-2032)
Based on Drug Type segmentation, the chemotherapy segment is the largest in the global market in 2025
Based on Distribution channel segmentation, the hospital pharmacies segment is anticipated to hold the majority of the global market.
On the basis of region, North America was the leading revenue generator in 2024
Desmoid Tumors Market- Segmentation Analysis:
The Global Desmoid Tumors Market is segmented on the basis of Drug Type, Distribution channel, and Region.
The market is divided into five categories based on Drug Type: Non-steroidal anti-inflammatory drugs (NSAIDs), Chemotherapy, Targeted Therapy, Hormone Therapy and Others. The chemotherapy segment is the largest in the global market in 2025, and it is expected to continue to dominate the market during the forecast period. Chemotherapy, while traditionally associated with systemic side effects, remains an important treatment option, particularly for aggressive or inoperable tumors. Combination drug regimens tailored to individual patient needs have increased efficacy and tolerability. Furthermore, ongoing research into new chemotherapeutic agents with better safety profiles is expected to fuel growth in this segment. Despite its challenges, chemotherapy is still an important part of the treatment arsenal.
The market is divided into three categories based on Distribution channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is expected to account for the majority of the global market during the forecast period. Hospital pharmacies are an important distribution channel for desmoid tumor treatments because they have direct access to patients receiving treatment in healthcare facilities. These pharmacies ensure the availability of essential medications and serve as a vital link between healthcare providers and patients. Their role in managing medication supply and offering counseling services is critical to the overall treatment process.
Desmoid Tumors Market- Geographical Insights
North America is the largest regional segment in the global desmoid tumors market, and it is expected to maintain its lead position during the forecast period. Rising healthcare expenditure, rapid adoption of technological advancements, growing awareness, and rising prevalence of desmoid tumors in North America all contribute to the market's growth. Imaging advancements, such as MRI and CT scans, have improved the ability to detect and locate desmoid tumors.
The Asia-Pacific region is expected to have the highest CAGR in the global market over the forecast period. The growing patient population, increased healthcare investments and infrastructure development, and increased awareness of rare diseases and access to healthcare are the primary drivers of the desmoid tumors market in Asia-Pacific.
Desmoid Tumors Market- Competitive Landscape:
The desmoid tumors market is competitive, with pharmaceutical companies and research institutions all working to develop effective treatment options. Key players include Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, and Amneal Pharmaceuticals LLC, which has participated in clinical trials for targeted therapies. Smaller biotech firms and academic institutions focused on innovative research and development contribute to the market as well. Competition is driven by the need to improve treatment outcomes, reduce side effects, and meet patients' unmet medical needs. This includes both the development of new therapies, such as targeted drugs and immunotherapies, and the enhancement of existing treatments. Regulatory approvals, clinical trial results, and patentability all have an impact on the competitive environment.
Recent Developments:
In August, 2023, Horizon Therapeutics Plc has announced the launch of Krystexxa® (PEGylated brentuximab vedotin) for injection in the United States for the treatment of adult patients with unresectable or recurrent locally advanced or metastatic soft tissue sarcoma (STS) who have previously received anthracycline-containing chemotherapy.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DESMOID TUMORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Horizon Therapeutics Plc
Strides Pharma Science Limited
Teva Pharmaceutical Industries Ltd
Amneal Pharmaceuticals LLC
Hikma Pharmaceuticals PLC
Natco Pharma Ltd
Lupin, Zydus Lifesciences
Mylan N.V.
Assertio Holdings, Inc.
Mayne Pharma Group Limited
Alembic Pharmaceuticals Limited, Aprazer
Ayala Pharmaceuticals
SpringWorks Therapeutics, Inc
Iterion Therapeutics
Novartis AG
Apotex Inc.
Bayer AG
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd
Endo International plc
Abbott
Getwell Pharmaceuticals
Others
GLOBAL DESMOID TUMORS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
Non-steroidal anti-inflammatory drugs(NSAIDs)
Chemotherapy
Targeted Therapy
Hormone Therapy
Others
GLOBAL DESMOID TUMORS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
GLOBAL DESMOID TUMORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA
Table of Contents
303 Pages
- 1. Deep Brain Stimulation In Parkinson’s Disease Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
- 2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Deep Brain Stimulation In Parkinson’s Disease Market Snippet by Product
- 2.1.2. Deep Brain Stimulation In Parkinson’s Disease Market Snippet by End-use
- 2.1.3. Deep Brain Stimulation In Parkinson’s Disease Market Snippet by Country
- 2.1.4. Deep Brain Stimulation In Parkinson’s Disease Market Snippet by Region
- 2.2. Competitive Insights
- 3. Deep Brain Stimulation In Parkinson’s Disease Key Market Trends
- 3.1. Deep Brain Stimulation In Parkinson’s Disease Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Deep Brain Stimulation In Parkinson’s Disease Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Deep Brain Stimulation In Parkinson’s Disease Market Opportunities
- 3.4. Deep Brain Stimulation In Parkinson’s Disease Market Future Trends
- 4. Deep Brain Stimulation In Parkinson’s Disease Industry Study
- 4.1. PEST Analysis
- 4.2. Porter’s Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
- 5. Deep Brain Stimulation In Parkinson’s Disease Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
- 6. Deep Brain Stimulation In Parkinson’s Disease Market Landscape
- 6.1. Deep Brain Stimulation In Parkinson’s Disease Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players’ Analysis
- 6.2.2. Emerging Players’ Analysis
- 7. Deep Brain Stimulation In Parkinson’s Disease Market – By Product
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Product, 2024 & 2032 (%)
- 7.1.2. Single-channel
- 7.1.3. Dual-channel
- 8. Deep Brain Stimulation In Parkinson’s Disease Market – By End-use
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By End-use, 2024 & 2032 (%)
- 8.1.2. Hospitals
- 8.1.3. Ambulatory Surgical Centers
- 8.1.4. Neurology Clinics
- 8.1.5. Research Centers
- 9. Deep Brain Stimulation In Parkinson’s Disease Market– By Geography
- 9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 9.2. North America
- 9.2.1. Overview
- 9.2.2. Deep Brain Stimulation In Parkinson’s Disease Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.2.6. U.S.
- 9.2.6.1. Overview
- 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.6.3. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.2.6.4. U.S. Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.2.7. Canada
- 9.2.7.1. Overview
- 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.7.3. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.2.7.4. Canada Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3. Europe
- 9.3.1. Overview
- 9.3.2. Deep Brain Stimulation In Parkinson’s Disease Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.6. Germany
- 9.3.6.1. Overview
- 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.6.3. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.6.4. Germany Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.7. UK
- 9.3.7.1. Overview
- 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.7.3. UK Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.7.4. UK Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.8. France
- 9.3.8.1. Overview
- 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.8.3. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.8.4. France Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.9. Italy
- 9.3.9.1. Overview
- 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.9.3. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.9.4. Italy Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.10. Spain
- 9.3.10.1. Overview
- 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.10.3. Spain Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.10.4. Spain Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.11. The Netherlands
- 9.3.11.1. Overview
- 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.11.3. The Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.11.4. The Netherlands Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.12. Sweden
- 9.3.12.1. Overview
- 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.12.3. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.12.4. Sweden Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.13. Russia
- 9.3.13.1. Overview
- 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.13.3. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.13.4. Russia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.14. Poland
- 9.3.14.1. Overview
- 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.14.3. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.14.4. Poland Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.3.15. Rest of Europe
- 9.3.15.1. Overview
- 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.15.3. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.3.15.4. Rest of the Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Deep Brain Stimulation In Parkinson’s Disease Key Manufacturers in Asia Pacific
- 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4. APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.5. APAC Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.6. China
- 9.4.6.1. Overview
- 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.6.3. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.6.4. China Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.7. India
- 9.4.7.1. Overview
- 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.7.3. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.7.4. India Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.8. Japan
- 9.4.8.1. Overview
- 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.8.3. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.8.4. Japan Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.9. South Korea
- 9.4.9.1. Overview
- 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.9.3. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.9.4. South Korea Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.10. Australia
- 9.4.10.1. Overview
- 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.10.3. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.10.4. Australia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.11. Indonesia
- 9.4.11.1. Overview
- 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.11.3. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.11.4. Indonesia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.12. Thailand
- 9.4.12.1. Overview
- 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.12.3. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.12.4. Thailand Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.13. Philippines
- 9.4.13.1. Overview
- 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.13.3. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.13.4. Philippines Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.4.14. Rest of APAC
- 9.4.14.1. Overview
- 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.14.3. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.4.14.4. Rest of APAC Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.5. Latin America (LATAM)
- 9.5.1. Overview
- 9.5.2. Deep Brain Stimulation In Parkinson’s Disease Key Manufacturers in Latin America
- 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4. LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.5.5. LATAM Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.5.6. Brazil
- 9.5.6.1. Overview
- 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.6.3. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.5.6.4. Brazil Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.5.7. Mexico
- 9.5.7.1. Overview
- 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.7.3. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.5.7.4. Mexico Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.5.8. Argentina
- 9.5.8.1. Overview
- 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.8.3. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.5.8.4. Argentina Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.5.9. Colombia
- 9.5.9.1. Overview
- 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.9.3. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.5.9.4. Colombia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.5.10. Rest of LATAM
- 9.5.10.1. Overview
- 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.10.3. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.5.10.4. Rest of LATAM Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.6. Middle East and Africa (MEA)
- 9.6.1. Overview
- 9.6.2. Deep Brain Stimulation In Parkinson’s Disease Key Manufacturers in Middle East and Africa
- 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4. MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.6.5. MEA Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.6.6. Saudi Arabia
- 9.6.6.1. Overview
- 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.6.3. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.6.6.4. Saudi Arabia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.6.7. UAE
- 9.6.7.1. Overview
- 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.7.3. UAE Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.6.7.4. UAE Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.6.8. Israel
- 9.6.8.1. Overview
- 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.8.3. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.6.8.4. Israel Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.6.9. Turkey
- 9.6.9.1. Overview
- 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.9.3. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.6.9.4. Turkey Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.6.10. Algeria
- 9.6.10.1. Overview
- 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.10.3. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.6.10.4. Algeria Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.6.11. Egypt
- 9.6.11.1. Overview
- 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.11.3. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.6.11.4. Egypt Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 9.6.12. Rest of MEA
- 9.6.12.1. Overview
- 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.12.3. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
- 9.6.12.4. Rest of MEA Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 10. Key Vendor Analysis- Deep Brain Stimulation In Parkinson’s Disease Industry
- 10.1. Competitive Benchmarking
- 10.1.1. Competitive Dashboard
- 10.1.2. Competitive Positioning
- 10.2. Company Profiles
- 10.2.1. Abbott
- 10.2.2. Boston Scientific Corporation
- 10.2.3. Medtronic
- 10.2.4. Others
- 11. 360 Degree AnalystView
- 12. Appendix
- 12.1. Research Methodology
- 12.2. References
- 12.3. Abbreviations
- 12.4. Disclaimer
- 12.5. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
